Clinical trial / 2014
Vitamin E (alpha tocopherol) at 2000 IU/d slowed functional decline in patients with mild to moderate Alzheimer disease compared with placebo.
A randomized trial investigated the effects of 2000 IU/d of alpha tocopherol, 20 mg/d of memantine, their combination, or placebo in 613 patients with mild to moderate Alzheimer disease over a mean follow-up of 2.27 years. Over follow-up, ADCS-ADL scores declined by 3.15 units less in the alpha tocopherol group compared with placebo (95% CI, 0.92 to 5.39; adjusted P = .03), corresponding to an annualized 19% delay in clinical progression. Decline in the memantine group was not significantly different from placebo (1.98 units less; 95% CI, -0.24 to 4.20; adjusted P = .40), nor were significant differences seen for combination therapy. Caregiver time increased least with alpha tocopherol, while serious adverse events for infections or infestations were higher in the memantine and combination groups compared with placebo.
- Study type
- Double-blind, placebo-controlled randomized clinical trial
- Who was studied
- 613 patients with mild to moderate Alzheimer disease taking an acetylcholinesterase inhibitor (561 analyzed)
- What was measured
- Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score
THE PAPER
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. JAMA, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.